MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.

被引：0
|
作者：
Nastoupil, Loretta J.
Song, Yuqin
Sehn, Laurie Helen
Sarkozy, Clementine
Zinzani, Pier Luigi
Silvestre, Antonio Salar
Zhang, Jun
Huang, Sha
Wang, Julie
Delarue, Richard
Trotman, Judith
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[3] Univ British Columbia, Vancouver, BC, Canada
[4] Inst Curie, Paris, France
[5] Univ Bologna, Bologna, Italy
[6] Hosp del Mar, Barcelona, Spain
[7] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
[8] BeiGene USA Inc, San Mateo, CA USA
[9] BeiGene Beijing Co Ltd, Beijing, Peoples R China
[10] Univ Sydney, Concord Repatriat Gen Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7590
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, OpenLabel, Phase 1b Trial
    Strati, Paolo
    Christian, Beth
    Martin, Peter
    Champion, Becky
    Coleman, Morton
    Agajanian, Richy
    Smith, Sonali M.
    Venugopal, Parameswaran
    Lossos, Izidore S.
    Kridel, Robert
    Calvo, Roser
    Higgins, Kara
    Stephens, Deborah M.
    BLOOD, 2022, 140 : 3606 - 3608
  • [42] A Phase 1b/3 Randomized, Double-Blind, 3-Stage Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
    Leonard, John
    Batlevi, Connie Lee
    Gabrail, Nashat
    Pagel, John M.
    Yang, Jay
    Whalen, Jennifer
    Adib, Deyaa
    Morschhauser, Franck
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S279 - S279
  • [43] Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma
    Grunenberg, Alexander
    Kaiser, Lisa M.
    Woelfle, Stephanie
    Schmelzle, Birgit
    Viardot, Andreas
    Moeller, Peter
    Barth, Thomas F. E.
    Muche, Rainer
    Dreyhaupt, Jens
    Buske, Christian
    FUTURE ONCOLOGY, 2020, 16 (13) : 817 - 825
  • [44] Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma
    de Vos, Sven
    Goy, Andre
    Dakhil, Shaker R.
    Saleh, Mansoor N.
    McLaughlin, Peter
    Belt, Robert
    Flowers, Christopher R.
    Knapp, Mark
    Hart, Lowell
    Patel-Donnelly, Dipti
    Glenn, Martha
    Gregory, Stephanie A.
    Holladay, Charles
    Zhang, Tracy
    Boral, Anthony L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) : 5023 - 5030
  • [45] Chimeric anti-CD20 monoclonal antibody (rituximab) plus G-CSF in relapsed B-cell-lymphoma:: A phase I/II clinical trial.
    van der Kolk, LE
    Grillo-López, AJ
    Gerritsen, W
    Jonkhoff, AR
    Baars, J
    van Oers, MHJ
    BLOOD, 1998, 92 (10) : 241B - 241B
  • [46] Phase Ib/II trial of polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed/refractory follicular lymphoma: primary analysis of the full efficacy population
    Diefenbach, C. S.
    McMillan, A.
    Kahl, B. S.
    Miall, F.
    Banerjee, L.
    Briones, J.
    Cordoba, R.
    Abrisqueta, P.
    Hirata, J.
    Chang, Y.
    Musick, L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 113 - 114
  • [47] Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial
    Diefenbach, Catherine
    Kahl, Brad S.
    Banerjee, Lalita
    McMillan, Andrew K.
    Miall, Fiona
    Briones, Javier
    Cordoba, Raul
    Hirata, Jamie
    Chang, YiMeng
    Musick, Lisa
    Abrisqueta, Pau
    BLOOD, 2019, 134
  • [48] AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
    Leonard, John P.
    Trneny, Marek
    Izutsu, Koji
    Fowler, Nathan H.
    Hong, Xiaonan
    Zhu, Jun
    Zhang, Huilai
    Offner, Fritz
    Scheliga, Adriana
    Nowakowski, Grzegorz S.
    Pinto, Antonio
    Re, Francesca
    Fogliatto, Laura Maria
    Scheinberg, Phillip
    Flinn, Ian W.
    Moreira, Claudia
    Liu, David
    Kalambakas, Stacey
    Fustier, Pierre
    Wu, Chengqing
    Gribben, John G.
    BLOOD, 2018, 132
  • [49] Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).
    Andorsky, David Jacob
    Yacoub, Abdulraheem
    Melear, Jason M.
    Coleman, Morton
    Kolibaba, Kathryn S.
    Brooks, Heather Dawn
    Bitran, Jacob D.
    Fanning, Suzanne R.
    Lansigan, Frederick
    Ricker, Justin L.
    Foon, Kenneth A.
    Liu, Dongfang
    Llorente, Mary
    Li, Jiahui
    Sharman, Jeff Porter
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide plus rituximab (R2) vs. rituximab plus placebo in relapsed/refractory indolent non-Hodgkin lymphoma
    Izutsu, Koji
    Minami, Yosuke
    Fukuhara, Noriko
    Terui, Yasuhito
    Jo, Tatsuro
    Yamamoto, Go
    Ishikawa, Takayuki
    Kobayashi, Tsutomu
    Kiguchi, Toru
    Nagai, Hirokazu
    Ohtsu, Tomoko
    Kalambakas, Stacey
    Fustier, Pierre
    Midorikawa, Shuichi
    Tobinai, Kensei
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (03) : 409 - 416
12345